Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT for Oligometastatic Bone Disease
NCT02880319Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial in bone metastasis and cancer (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Local Control Rate at 6 months. Started Nov 2016; status: active, not recruiting.
02
Conditions
bone metastasiscancer
Beyond the preview
Go deeper on NCT02880319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880319.